Cargando…
Prevention and Therapy of Metastatic HER-2(+) Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine
Vaccines are a promising therapeutic alternative to monoclonal antibodies against HER-2(+) breast cancer. We present the preclinical activity of an ES2B-C001, a VLP-based vaccine being developed for human breast cancer therapy. FVB mice challenged with HER-2(+) mammary carcinoma cells QD developed p...
Autores principales: | Ruzzi, Francesca, Palladini, Arianna, Clemmensen, Stine, Strøbæk, Anette, Buijs, Nicolaas, Domeyer, Tanja, Dorosz, Jerzy, Soroka, Vladislav, Grzadziela, Dagmara, Rasmussen, Christina Jo, Nielsen, Ida Busch, Soegaard, Max, Semprini, Maria Sofia, Scalambra, Laura, Angelicola, Stefania, Landuzzi, Lorena, Lollini, Pier-Luigi, Thorn, Mette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599132/ https://www.ncbi.nlm.nih.gov/pubmed/36289916 http://dx.doi.org/10.3390/biomedicines10102654 |
Ejemplares similares
-
IFN-γ and CD38 in Hyperprogressive Cancer Development
por: Angelicola, Stefania, et al.
Publicado: (2021) -
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression
por: Giusti, Veronica, et al.
Publicado: (2021) -
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
por: Ruzzi, Francesca, et al.
Publicado: (2023) -
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R
por: De Giovanni, Carla, et al.
Publicado: (2019) -
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
por: De Giovanni, Carla, et al.
Publicado: (2021)